<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>01</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Results of Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma (MM) and Renal Impairment: A Retrospective Single-Center Study</title>
    <FirstPage>64</FirstPage>
    <LastPage>74</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Maiia</FirstName>
        <LastName>Firsova</LastName>
        <affiliation locale="en_US">Department of High-Dose Chemotherapy of Paraproteinemic Hemoblastoses, FSFI &#xAB;National Research Center for Hematology&#xBB;, Moscow, Russian Federation</affiliation>
      </Author>
      <Author>
        <FirstName>Maxim</FirstName>
        <LastName>Solovev</LastName>
        <affiliation locale="en_US">Department of High-Dose Chemotherapy of Paraproteinemic Hemoblastoses, FSFI &#xAB;National Research Center for Hematology&#xBB;, Moscow, Russian Federation</affiliation>
      </Author>
      <Author>
        <FirstName>Daria</FirstName>
        <LastName>Mironova</LastName>
        <affiliation locale="en_US">Department of High-Dose Chemotherapy of Paraproteinemic Hemoblastoses, FSFI &#xAB;National Research Center for Hematology&#xBB;, Moscow, Russian Federation</affiliation>
      </Author>
      <Author>
        <FirstName>Larisa</FirstName>
        <LastName>Mendeleeva</LastName>
        <affiliation locale="en_US">Department of High-Dose Chemotherapy of Paraproteinemic Hemoblastoses, FSFI &#xAB;National Research Center for Hematology&#xBB;, Moscow, Russian Federation</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2022</Year>
        <Month>03</Month>
        <Day>28</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2023</Year>
        <Month>11</Month>
        <Day>29</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: To assess the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM) patients with acute renal failure.
&#xD;

Materials and Methods: A retrospective single-center study included 64 patients (30 men, 34 women) with MM and kidney damage at the onset of the disease, aged 19 to 65 years (median 54), who underwent auto-HSCT from 2013 to 2019. 23 patients (36%) were dialysis-dependent at the time of diagnosis. The analysis was carried out in two groups: the "HD-" group (patients who were independent of hemodialysis during auto-HSCT, n = 54), and the "HD +" group (patients who underwent auto-HSCT while treated with programmed hemodialysis, n = 10). Research results were statistically processed using the Statistica software (version 10.0); the data obtained were presented graphically. Statistical analysis was performed using survival analysis (using the Kaplan-Meier method, with a Log-Rank Test) and frequency analysis (using contingency tables and Fisher's test).
&#xD;

Results: The patients dependent on hemodialysis were significantly more likely to require red blood cell transfusions compared to the dialysis-independent patients (100% versus 35%, p = 0.0001). Reactivation of a herpes viral infection and reversible toxic encephalopathy developed significantly more often in the patients from the &#x201C;HD +&#x201D; group compared with the patients from the &#x201C;HD-&#x201D; group (30% versus 6%, p = 0.04 and 20% versus 0%, p = 0.02, respectively). As a result of the treatment (induction + auto-HSCT), 14 patients (61%) became hemodialysis-independent. There was no transplant-related mortality. With a median follow-up of 48 months, the 5-year overall survival (OS) and progression-free survival (PFS) were 70% and 42%, respectively.
&#xD;

Conclusion: Auto-HSCT is a safe and effective treatment for patients with MM complicated by acute kidney injury. Fourteen of 23 (61%) patients became dialysis-independent.</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1818</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1818/1017</pdf_url>
  </Article>
</Articles>
